Amgen Inc. outperformed Wall Street’s quarterly profit estimates as it moves forward with plans to crack the ...

The obesity drug price wars are finally starting. After being publicly lambasted for the high cost of their weight-loss shots ...

Obesity is common in our society for humans and our pets. Spring is a good time to consider the impacts of winter ...

The pharmaceutical firm Novo Nordisk is pursuing a multi-pronged strategy to regain market share that it has lost to Eli ...

Yet the disparities by sex, race/ethnicity, and location pale in comparison to a striking overall lack of adoption.

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

A new study found more than two-thirds of Reserve and Guard troops are overweight, prompting a scathing rebuke of lax ...

Eli Lilly shares dropped Thursday as Novo Nordisk notched a coverage win for its obesity drug, a sign of the competition in ...

The Danish drugmaker is expanding Wegovy access via telehealth providers like Hims and Ro. But the gap with Eli Lilly is only ...

Researchers found that the impact of polyphenols rutin and genistein on the human fecal metabolome varies significantly by ...

Disparities in prescribing semaglutide and tirzepatide for obesity reveal social factors affecting access and highlight the ...

Novo Nordisk has launched its hugely popular weight-loss drug Wegovy in Thailand, an executive of the Danish drugmaker's ...